Date of webinar: Monday June 16th, 2025 (1pm-2pm (ET))
Webinar details: The FARES-II trial: Is it time to replace FP with PCC as first-line therapy for coagulopathic bleeding in cardiac surgery?
Key takeaways
- The FARES-II study found that prothrombin complex concentrates (PCCs) were superior to frozen plasma (FP) for hemostatic response in the management of excessive bleeding related to coagulation factor deficiency in patients undergoing cardiac surgery.
- The greater hemostatic efficacy of PCC over FP reported in the FARES-II study was shown across multiple endpoints and was not accompanied by an increase in thromboembolic events.
- The FARES-II study found that patients who received PCC had fewer adverse events and acute kidney injuries compared to those who received FP.
Publications
Webinar recording
Suggested citation
Karkouti, K. (2025). The FARES-II trial: Is it time to replace FP with PCC as first-line therapy for coagulopathic bleeding in cardiac surgery? [Slide deck]. Breakthroughs in blood: Advancements into Action webinar series. Canadian Blood Services. https://profedu.blood.ca/en/transfusion/best-practices/breakthroughs-blood-advancing-practice-through-research
Resources
FAQ: Use of prothrombin complex concentrates (PCCS) in cardiac surgery for postoperative coagulopathy.
176.55 KB
12.1 MB
Suggested citation
Callum, J. & Karkouti, K. (2025). FAQ: Use of prothrombin complex concentrates (PCCS) in cardiac surgery for postoperative coagulopathy. [Slide deck]. Breakthroughs in blood: Advancements into Action webinar series. Canadian Blood Services. https://profedu.blood.ca/en/transfusion/best-practices/breakthroughs-blood-advancing-practice-through-research